Completed PHASE1 INTERVENTIONAL NCT00528684

Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas

A Phase I/II Clinical Trial to Evaluate Dose Limiting Toxicity and Efficacy of Intralesional Administration of REOLYSIN® for the Treatment of Patients With Histologically Confirmed Recurrent Malignant Gliomas

Sponsor: Oncolytics Biotech

Conditions Malignant Glioma

Interventions REOLYSIN®

Updated 6 times since 2017 Last updated: Sep 30, 2014 Started: Jul 31, 2006 Primary completion: Apr 30, 2010 Completion: Jun 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Malignant Glioma and is currently completed. Oncolytics Biotech leads this study, which shows 6 recorded versions since 2006 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jul 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Oncolytics Biotech

Data source: Oncolytics Biotech

For direct contact, visit the study record on ClinicalTrials.gov .

Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas

Status Flow

Change History

Eligibility Summary

Contact Information

Study Locations

Related Trials